| Literature DB >> 27853655 |
Anthony Torres1, Jonna Westover1, Michael Benson1, Randall Johnson1, Annelise Dykes1.
Abstract
The killing activity of natural killer cells is largely regulated by the binding of class I human leukocyte antigen cognate ligands to killer cell immunoglobulin - like receptor proteins. The killer cell immunoglobulin - like receptor gene - complex contains genes that activate and others that inhibit the killing state of natural killer cells depending on the binding of specific human leukocyte antigen cognate ligands. It has been suggested in previous publications that activating human leukocyte antigen/killer - cell immunoglobulin - like receptor complexes are increased in people with autism. We present data, which suggests that an activating cB01/tA01 killer cell immunoglobulin - like receptor gene - content haplotype and the cognate ligand human leukocyte antigen - C1k that activates this haplotype is significantly increased in autism. This is an important observation suggesting that the interaction between two proteins encoded on different chromosomes increases natural killer cell killing in autism.Entities:
Keywords: Autism; Human leukocyte antigen (HLA) alleles; KIR gene; Killer - cell immunoglobulin - like receptors (KIR); Transmission disequilibrium test (TDT)
Year: 2016 PMID: 27853655 PMCID: PMC5108574 DOI: 10.4172/2165-7890.1000171
Source DB: PubMed Journal: Autism Open Access ISSN: 2165-7890
Figure 1location of HLA ligands on human chromosome 6 and the KIR gene complex on chromosome 19
Comparison of KIR Genotype and KIR Gene Copy Number in 89 AGRE Subjects. Note: KIR genotyping only determines if a gene is absent or present; whereas, the GCN determines the number of specific KIR genes in a diploid individual. By dividing the GCN for each KIR gene by the genotype a gene content ratio is obtained.
| 61/56 = 1.09 | ||||||||
| 2DS2 | 56 | 33 | 33 | 51 | 5 | 0 | 61 | |
| 2DL2 | 53 | 36 | 36 | 50 | 3 | 0 | 56 | 56/53 = 1.06 |
| 2DL3 | 77 | 12 | 12 | 45 | 32 | 0 | 109 | 109/77 = 1.42 |
| 2DL5c | 27 | 62 | 62 | 25 | 2 | 0 | 29 | 29/27 = 1.07 |
| 2DS35c | 27 | 62 | 62 | 25 | 2 | 0 | 29 | 29/27 = 1.07 |
| 2DP1 | 88 | 1 | 1 | 29 | 59 | 0 | 147 | 147/88 = 1.67 |
| 2DL1 | 88 | 1 | 1 | 26 | 62 | 0 | 150 | 150/88 = 1.70 |
| 3DP1 | 89 | 0 | 0 | 4 | 78 | 7 | 181 | 181/89 = 2.03 |
| 2DL4 | 89 | 0 | 0 | 4 | 78 | 7 | 181 | 181/89 = 2.03 |
| 3DL1 | 85 | 4 | 4 | 39 | 45 | 1 | 132 | 132/85 = 1.55 |
| 3DS1 | 42 | 47 | 47 | 35 | 7 | 0 | 49 | 49/42 = 1.17 |
| 2DL5t | 44 | 45 | 45 | 40 | 4 | 0 | 48 | 48/44 = 1.09 |
| 2DS35t | 44 | 45 | 45 | 40 | 4 | 0 | 48 | 48/44 = 1.09 |
The Average Number of KIR Activating (S) and Inhibitory (L) Genes in AGRE Subjects Compared to Average Number of (S) and (L) Genes in the Control Population [33]
| KIR genes | Average activating (S) genes/AGRE subject (n = 178) | Average inhibitory (L) genes/Control population (n = 9,024) | p value | OR |
|---|---|---|---|---|
| 2DS2, 2DS3/5c, 3DS1, 2DS3/5t, 2DS1, 2DS4 | 2.14 | 1.87 | 0.0029 | 1.19 |
| 3DL3, 2DL2, 2DL5c, 2DL1, 2DL4, 3DL1, 2DL5t, 3DL2, 2DL3 | 6.04 | 5.93 | 0.038 | 1.25 |
Figure 2Complete KIR gene haplotypes
Centromeric and Telomeric KIR Haplotypes Constructed From Individual GCNs Were Compared to 9024 KIR Normal Control Gene - Content Haplotype
| Haplotypes | Control | Autism | Fisher’s exact P | OR | 95% confidence interval |
|---|---|---|---|---|---|
| (n = 9,024) | (n = 178) | ||||
| Centromeric | |||||
| cA01 | 6,248 | 110 | 0.00001 | 0.53 | (0.40, 0.70) |
| cB01 | 1,184 | 41 | 0.0045 | 1.69 | (1.19, 2.39) |
| cB02 | 1,566 | 27 | 0.1576 | 0.73 | (0.49, 1.11) |
| cB03 | 26 | 0 | 1 | - | - |
| Telomeric | |||||
| tA01 | 6,968 | 130 | 0.00004 | 0.53 | (0.40, 0.71) |
| tB01 | 2,055 | 48 | 0.7347 | 1.06 | (0.76, 1.47) |
Complete KIR Haplotypes of AGRE Subjects versus Caucasian Controls [33].
Eight AGRE haplotypes could not be determined from the 178 possible haplotypes.
| KIR haplotypes | AGRE | Control | p value | Odds ratio |
|---|---|---|---|---|
| (n = 170) | (n = 9,024) | |||
| cA01/tA01 | 84 | 5,133 | 0.06 | 0.74 |
| cA01/tB01 | 23 | 1,114 | 0.638 | 1.11 |
| cB01/tB01 | 13 | 461 | 0.157 | 1.538 |
| cB02/tA01 | 17 | 1,112 | 0.41 | 0.791 |
| cB01/tA01 | 25 | 697 | 0.002 | 2.06 |
| cB02/tB01 | 8 | 480 | 0.863 | 0.879 |
HLA Ligand Activation or Inhibition of KIR Haplotypes.
| KIR Haplotypes | HLA ligands |
|---|---|
| cA01 | C1k Inhibits (2DL3), C2k Inhibits (2DL1) |
| cB01 | C1k Inhibits (2DL2), C1k Activates (2DS2), C2k Inhibits (2DL1) |
| cB02 | C1k Inhibits (2DL2), C1k Activates (2DS2) |
| tA01 | Bw4 Inhibits (3DL1), |
| tB01 | Bw4 Activates (3DS1), C2k Activates (2DS1) |
Centromeric haplotypes - - Bw4 is not a ligand and
Telomeric haplotypes - - C1k is not a ligand.
Inherited and Noninherited HLA - C Ligand Binding to the KIR Centromeric Haplotype cB01. 1 HLA - C1k (C*01, 03, 07, 08, 12, 14, 16) and 2 HLA - C2k (C*02, 04, 05, 06, 15, 17, 18) allotypes.
| Inherited HLA KIR ligands determined from HLA allotyping and genotyping | Noninherited HLA Ligands from HLA allotyping | KIR - HLA associations | ||||
|---|---|---|---|---|---|---|
| Haplotype | HLA ligand | % | HLA ligand1,2 | % | p value | OR |
| Centromeric | (42 subjects) | (39 subjects) | ||||
| cB01 | C1k/C1k (25) | 59.5 | C1k/C1k (13) | 33.3 | 0.026 | 2.941 |
| cB01 | C1k/C2k (15) | 35.7 | C1k/C2k (20) | 51.3 | 0.183 | 0.528 |
| cB01 | C2k/C2k (2) | 4.8 | C2k/C2k (6) | 15.4 | 0.146 | 0.275 |